Optimization of rituximab for the treatment of DLBCL (I): Dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1800-1806

  Murawski, N ^a   Pfreundschuh, M ^a   Zeynalova, S ^b   Poeschel, V ^a   Hanel M ^c   Held, G ^a   Schmitz, N ^d   Viardot, A ^e   Schmidt, C ^f   Hallek, M ^g   Witzens Harig, M ^h   Trumper L ⁱ   Rixecker, T ^a   Zwick, C ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Diffuse large B cell lymphoma; Dose dense rituximab; Elderly; Rituximab toxicity

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; GERIATRIC CARE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SINGLE DRUG DOSE; TREATMENT DURATION; VERY ELDERLY; AGING; BLOOD; CLINICAL TRIAL; COMMUNICABLE DISEASES; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INFECTION CONTROL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; DRUG FATALITY; DRUG RESPONSE; INTERNATIONAL PROGNOSTIC INDEX; OPEN STUDY;

ACYCLOVIR; AGED; AGED, 80 AND OVER; AGING; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VINCRISTINE;

EID: 84906849529     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu208     Document Type: Article

References (12)

1. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
2. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
3. Pfreundschuh M, Truemper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
4. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
5. Muller C, Murawski N, Wiesen MH et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012; 119: 3276-3284.
6. Pfreundschuh M, Muller C, Zeynalova S et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 2014; 123: 640-646.
7. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
8. WHO. Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva: WHO Press; 2008.
9. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
10. Wunderlich A, Kloess M, Reiser M et al. Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non- Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003; 14: 881-893.
11. Pfreundschuh M, Zeynalova S, Poeschel V et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dosedense rituximab: results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2008; 19(suppl 4): iv99.
12. Murawski N, Held G, Zeynalova S et al. Outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab applications given over an exteded period. J Clin Oncol 2012; 20: 516s.